標(biāo)題: Titlebook: Best Practices of Apheresis in Hematopoietic Cell Transplantation; Syed A. Abutalib,Anand Padmanabhan,Nina Worel Book 2020 Springer Nature [打印本頁(yè)] 作者: 小巷 時(shí)間: 2025-3-21 16:11
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation影響因子(影響力)
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation影響因子(影響力)學(xué)科排名
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation網(wǎng)絡(luò)公開度
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation被引頻次
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation被引頻次學(xué)科排名
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation年度引用
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation年度引用學(xué)科排名
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation讀者反饋
書目名稱Best Practices of Apheresis in Hematopoietic Cell Transplantation讀者反饋學(xué)科排名
作者: ANNUL 時(shí)間: 2025-3-21 22:02
Advances and Controversies in Hematopoietic Transplantation and Cell Therapyhttp://image.papertrans.cn/b/image/184236.jpg作者: 芳香一點(diǎn) 時(shí)間: 2025-3-22 01:11 作者: Buttress 時(shí)間: 2025-3-22 08:28
Springer Nature Switzerland AG 2020作者: A簡(jiǎn)潔的 時(shí)間: 2025-3-22 10:21 作者: packet 時(shí)間: 2025-3-22 14:36
Introduction and Rationale,With great pleasure, we present this inaugural edition of . as part of the handbook series on .. This project is a collaborative effort that spanned a time period of more than 2?years and included more than 20 experts, many whom are national leaders in their respected fields.作者: Crater 時(shí)間: 2025-3-22 19:22
Yann Desfougères,Adolfo Saiarditransplantation process. Apheresis facilities, which collect such cells, are integral part of this process, which includes its highly regulated arena. Many regulations and accreditations exist for this process with whom apheresis facilities should be familiar. The chapter provides an overview of the作者: 飛來(lái)飛去真休 時(shí)間: 2025-3-22 22:46 作者: harangue 時(shí)間: 2025-3-23 01:50
Hongying Lin,Karsten Lindner,Georg W. Mayra donor, and ensuring that the product is without additional risk to the recipient, continues to be of paramount importance. The evaluation of the donor’s medical eligibility and suitability is designed to identify and limit the risk of transmitting infectious, genetic, or neoplastic diseases to the作者: 600 時(shí)間: 2025-3-23 07:36
Hongying Lin,Karsten Lindner,Georg W. Mayrological diseases. Common strategies for peripheral blood CD34. cell mobilization include the use of hematopoietic growth factors alone or in combination with chemotherapy, resulting in a marked increase of CD34. cells in the peripheral blood. However, a significant proportion of patients fail to mo作者: Paleontology 時(shí)間: 2025-3-23 11:07 作者: 反復(fù)拉緊 時(shí)間: 2025-3-23 15:04
https://doi.org/10.1007/978-1-4612-5184-2eresis medicine. There is a need to collect the “correct number and the right type of cells” in the hematopoietic graft without the presence of contaminating cells that may adversely affect product’s efficacy. In the United States, currently two Food and Drug Administration-cleared devices are avail作者: 踉蹌 時(shí)間: 2025-3-23 19:46
P. Marche,A. Girard,S. Koutouzovplantation. Successful apheresis collection procedures cannot be performed without the establishment and maintenance of adequate venous access and appropriate anticoagulation of the extracorporeal circuit to sustain flow rates of 50–100?mL/min. This chapter discusses these practical considerations r作者: overwrought 時(shí)間: 2025-3-24 02:01
Experimental Biology and Medicine both the collection center and processing laboratory, and to facilitate concurrent quality assurance. Once established within a center, their use can also decrease costs by decreasing the number of days of growth factor used for mobilization and by decreasing the number of collection days or length作者: Ergots 時(shí)間: 2025-3-24 03:51 作者: Spartan 時(shí)間: 2025-3-24 07:47
Mabel Hokin-Neaverson,Gregory S. Parries an extracorporeal circuit. After separation of plasma from corpuscular blood components, the endogenous plasma is either replaced by a substitution fluid (therapeutic plasma exchange) or loaded in reusable adsorber columns, where immunoglobulins are adsorbed (immunoadsorption). Several indications 作者: deface 時(shí)間: 2025-3-24 11:17 作者: 強(qiáng)壯 時(shí)間: 2025-3-24 16:49 作者: Gerontology 時(shí)間: 2025-3-24 19:46
J. W. Herzig,L. H. Botelho,R. J. Solaroors and patients, including hypocalcemia due to citrate infusion, hemodynamic changes associated with fluid shifts, and/or depletion of cellular and plasma components. Moreover, adverse events may be unrelated to the apheresis procedure itself (e.g., hematomas and/or infections from line). In genera作者: CLOWN 時(shí)間: 2025-3-25 01:21
Jan-Bj?rn Osnes,H. Aass,T. Skomedal the maintenance of a safe and sufficient blood supply and is a integral component of the hematopoietic progenitor cell transplant programs. Although there are initial capital costs for starting such a program, there has been confirmation of its cost-effectiveness and importance. Guidelines for stem作者: 變態(tài) 時(shí)間: 2025-3-25 05:41 作者: CAGE 時(shí)間: 2025-3-25 07:49
2569-1376 k, featuring numerous helpful tables, algorithms, and figures, will be of high practical value for residents, fellows, faculty members and other healthcare personnel involved in hematopoietic cell transplantati978-3-319-55131-9Series ISSN 2569-1376 Series E-ISSN 2569-135X 作者: collagen 時(shí)間: 2025-3-25 15:02
Best Practices of Apheresis in Hematopoietic Cell Transplantation作者: tattle 時(shí)間: 2025-3-25 17:56
Book 2020heresis in pediatric donors and in resource-limiting environments are considered. This book, featuring numerous helpful tables, algorithms, and figures, will be of high practical value for residents, fellows, faculty members and other healthcare personnel involved in hematopoietic cell transplantati作者: Engaged 時(shí)間: 2025-3-25 23:11 作者: 支架 時(shí)間: 2025-3-26 03:37
Mobilization Strategies: HPC(A) Collections for Allogeneic Hematopoietic Cell Transplants,onors must undergo hematopoietic progenitor cells mobilization prior to collection. Hematopoietic progenitor cells mobilization in healthy donors is performed utilizing cytokines exclusively. Even among healthy donors, approximately 2–6% do not collect a minimum of 2 × 10. CD34. cells/kg body weight作者: Enthralling 時(shí)間: 2025-3-26 07:37
Hematopoietic Progenitor Cells, Apheresis and Therapeutic Cells, T-Cells Collection: Instrumentatiowhen evaluating and implementing the use of these devices. In addition, as with any complex medical device, the potential exists for instrument/process failure, in this case inadequate HPC(A) or TC content or the presence of cells in the product which are not desired. In many cases, such failures ar作者: foodstuff 時(shí)間: 2025-3-26 11:46 作者: NOT 時(shí)間: 2025-3-26 13:17
Red Blood Cell Exchange: When and Why?,ssenger lymphocyte syndrome. Mature donor lymphocytes start to produce isohemagglutinins against recipient’s erythrocytes causing a hemolysis that typically starts 1–2?weeks after the transplant. Reduction of circulating patient’s erythrocytes using RBC exchange transfusions is a possible prophylact作者: Acupressure 時(shí)間: 2025-3-26 17:20
Extracorporeal Photopheresis in Hematopoietic Cell Transplantation,ed mortality (TRM). The therapeutic action of ECP in steroid-dependent and steroid-refractory chronic GvHD has been demonstrated by a large body of clinical data including a prospective randomized trial. Steroid-sparing effect is a key feature of this therapeutic modality. Future perspectives of ECP作者: FUSC 時(shí)間: 2025-3-26 22:02 作者: 過(guò)去分詞 時(shí)間: 2025-3-27 04:49
Hongying Lin,Karsten Lindner,Georg W. Mayron regimens. As the most robust predictive factor for poor CD34. cell collection is the CD34. cell count in the peripheral blood before initiation of apheresis, a defined threshold helps to identify patients at risk and allows preemptive intervention to immediate rescue mobilization in these patient作者: Conspiracy 時(shí)間: 2025-3-27 07:42
Mabel Hokin-Neaverson,Gregory S. Parriesonors must undergo hematopoietic progenitor cells mobilization prior to collection. Hematopoietic progenitor cells mobilization in healthy donors is performed utilizing cytokines exclusively. Even among healthy donors, approximately 2–6% do not collect a minimum of 2 × 10. CD34. cells/kg body weight作者: 惡名聲 時(shí)間: 2025-3-27 10:14
https://doi.org/10.1007/978-1-4612-5184-2when evaluating and implementing the use of these devices. In addition, as with any complex medical device, the potential exists for instrument/process failure, in this case inadequate HPC(A) or TC content or the presence of cells in the product which are not desired. In many cases, such failures ar作者: 得意人 時(shí)間: 2025-3-27 14:52
Experimental Biology and Medicineagents or density gradient centrifugation with density gradient reagents to optimize processing results. These substances bear a potential risk for the BM cells and the recipients. In the beginning of the 1990s, apheresis technology was substantially improved. The latest innovations in this field we作者: Plaque 時(shí)間: 2025-3-27 18:00 作者: inscribe 時(shí)間: 2025-3-28 00:20
Jan-Bj?rn Osnes,H. Aass,T. Skomedaled mortality (TRM). The therapeutic action of ECP in steroid-dependent and steroid-refractory chronic GvHD has been demonstrated by a large body of clinical data including a prospective randomized trial. Steroid-sparing effect is a key feature of this therapeutic modality. Future perspectives of ECP作者: FLAG 時(shí)間: 2025-3-28 04:28 作者: 潛伏期 時(shí)間: 2025-3-28 08:44 作者: 駁船 時(shí)間: 2025-3-28 12:48
Yann Desfougères,Adolfo Saiardi Many regulations and accreditations exist for this process with whom apheresis facilities should be familiar. The chapter provides an overview of the most important regulatory aspects of Apheresis Collection Facilities and a framework of how to become familiar with them.作者: 不近人情 時(shí)間: 2025-3-28 15:48
P. Marche,A. Girard,S. Koutouzovropriate anticoagulation of the extracorporeal circuit to sustain flow rates of 50–100?mL/min. This chapter discusses these practical considerations regarding apheresis HPC collections and how one might maximize procedure efficacy and safety.作者: Outshine 時(shí)間: 2025-3-28 20:09 作者: restrain 時(shí)間: 2025-3-29 02:37
Anticoagulation and Other Periprocedural Considerations for Apheresis,ropriate anticoagulation of the extracorporeal circuit to sustain flow rates of 50–100?mL/min. This chapter discusses these practical considerations regarding apheresis HPC collections and how one might maximize procedure efficacy and safety.作者: Dappled 時(shí)間: 2025-3-29 06:37
Mabel Hokin-Neaverson,Gregory S. Parrieser focus on their implementation in the treatment of three hematological diseases, thrombotic microangiopathy, acquired coagulation inhibitors, and pure red cell aplasia after major ABO-incompatible allogenic hematopoietic stem cell transplantation.作者: 使尷尬 時(shí)間: 2025-3-29 07:23 作者: 創(chuàng)作 時(shí)間: 2025-3-29 11:45 作者: 率直 時(shí)間: 2025-3-29 16:48
Hongying Lin,Karsten Lindner,Georg W. Mayrlatory agencies, national and international registries, and accreditation bodies have facilitated the availability and safe provision of human cells, tissues, and cellular- and tissue-based products not only at local institutions but also through international exchange.作者: fabricate 時(shí)間: 2025-3-29 20:50 作者: 灰姑娘 時(shí)間: 2025-3-30 00:32
FACT-JACIE Standards: Common Citations and How Best to Avoid Them, integrate into the collection of hematopoietic progenitor cell (HPC) products to address and avoid these citations as well as to provide high-quality cells to patients will be discussed. The trends discussed in this chapter reflect inspections performed by the Foundation for Accreditation of Cellular Therapy (FACT).作者: Vital-Signs 時(shí)間: 2025-3-30 07:46
Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection,latory agencies, national and international registries, and accreditation bodies have facilitated the availability and safe provision of human cells, tissues, and cellular- and tissue-based products not only at local institutions but also through international exchange.作者: deceive 時(shí)間: 2025-3-30 10:56 作者: GLARE 時(shí)間: 2025-3-30 16:08
Book 2020esis, with the aim of identifying current trends and best practices. Readers will find up-to-date guidance on donor evaluation, CD34.+. cell mobilization strategies, options and selection of apheresis device, anticoagulation techniques in apheresis, the role of prediction algorithms in determining p作者: Acumen 時(shí)間: 2025-3-30 17:32
Experimental Biology and Medicine of a collection, leading to a decrease in number of blood products transfused during collection since platelet loss can be minimized. Many approaches to predictive algorithms have been tried, and this chapter presents an overview of their history as well as a useful general strategy for current practice.作者: 閃光你我 時(shí)間: 2025-3-30 23:33
Concepts and Rationale for Using Predictive Algorithms for Hematopoietic Progenitor Cell Apheresis of a collection, leading to a decrease in number of blood products transfused during collection since platelet loss can be minimized. Many approaches to predictive algorithms have been tried, and this chapter presents an overview of their history as well as a useful general strategy for current practice.作者: certain 時(shí)間: 2025-3-31 03:56 作者: Evacuate 時(shí)間: 2025-3-31 05:49 作者: paragon 時(shí)間: 2025-3-31 12:29
Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection,a donor, and ensuring that the product is without additional risk to the recipient, continues to be of paramount importance. The evaluation of the donor’s medical eligibility and suitability is designed to identify and limit the risk of transmitting infectious, genetic, or neoplastic diseases to the作者: 一條卷發(fā) 時(shí)間: 2025-3-31 14:26 作者: 小教堂 時(shí)間: 2025-3-31 20:54
Mobilization Strategies: HPC(A) Collections for Allogeneic Hematopoietic Cell Transplants,e preferred graft source for allogeneic hematopoietic cell transplantation. There are advantages and disadvantages of utilizing peripheral blood-mobilized hematopoietic progenitor cells compared to bone marrow. According to National Marrow Donor Program (NMDP) guidelines, no more than 20?mL of marro作者: 使人入神 時(shí)間: 2025-4-1 00:13
